

TRANSMITTAL
FORM

SEP 07 1999
PATENT & TRADEMARK OFFICE
JC5

Application Serial Number	09/338,063
Filing Date	June 23, 1999
First Named Inventor	Goto et al.
Group Art Unit	1643
Examiner Name	Not yet assigned
Attorney Docket No.	FJN-060DV2 (3999/63)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets _____]	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)	<input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) Submission of Paper Copy and Computer Readable Copy of Sequence Listing for Invention Containing Nucleotide and/or Amino Acid Sequence
<input type="checkbox"/> Information Disclosure Statement Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations	<input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	 Paper Copy of Sequence Listing and 1 diskette of Sequence Listing
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> After Allowance Communication to Group	 Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		

CORRESPONDENCE ADDRESS

SIGNATURE BLOCK

Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

Date: September 1, 1999
Reg. No. 44,244
Tel. No.: (617) 248-7044
Fax No.: (617) 248-7100

Respectfully submitted,

Ronda P. Moore, D.V.M.
Ronda P. Moore, D.V.M.
Attorney for Applicants
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110



WD
GP. 16
PATENT
Attorney Docket No. FJN-060DV
(3999/63)

BOX
SEQ.

RECEIVED

SEP 10 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APPLICANT(S): Goto et al.
SERIAL NO.: 09/338,063 GROUP NO.: 1643
FILING DATE: June 23, 1999 EXAMINER: Not yet assigned
TITLE: NOVEL PROTEINS AND METHODS FOR PRODUCING THE
PROTEINS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 1st day of September 1, 1999.

Julie Westhaver
Julie Westhaver

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith is/are:

Transmittal Form (1 pg.); Submission of Paper Copy and Computer Readable Copy of Sequence Listing for Invention Containing Nucleotide and/or Amino Acid Sequence (2 pgs.); Paper Copy of Sequence Listing (69 pgs.); Computer Readable Copy of Sequence Listing (1 diskette); Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.); and postcard.



PATENT
Attorney Docket No. FJN-060DV2
(3999/63)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Goto et al.

SERIAL NO.: 09/338,063 GROUP NO.: 1643

FILING DATE: June 23, 1999 EXAMINER: Not yet assigned

TITLE: NOVEL PROTEINS AND METHODS FOR PRODUCING THE PROTEINS

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**SUBMISSION OF PAPER COPY AND COMPUTER READABLE COPY
OF SEQUENCE LISTING FOR INVENTION
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. This replies to the Notice to Company with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 5, 1999.
 A copy of the Notice to Company with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed.

2. Submitted herewith is/are
(check each item as applicable)
 - A. a paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier.

 - B. a copy, in computer readable form, of the Sequence Listing for this application.

13

STATEMENT

3. I hereby state that:

- A. the content of the paper and computer readable copies submitted herewith are the same.
- B. the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on pages 1 to 79 of the Sequence Listing in the original specification as filed.
- C. this submission includes no new matter.

Respectfully submitted,

Date: September 1, 1999
Reg. No. 44,244

Tel. No.: (617) 248-7044
Fax No.: (617) 248-7100

Ronda P. Moore, D.V.M.

Ronda P. Moore, D.V.M.
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Rmoore3999/63.849929-1



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

09/323,063 06/23/99 GOTO

MAIL F/TN-0600DV263

RECEIVED

0242/0805

SEP 13 1999

NOT ASSIGNED

021323
TESTA, HIRWITZ & THIBEAULT
HIGH STREET TOWER
125 HIGH STREET
BOSTON, MA 02110

TECH CENTER 1600/2900

SEP 07 1999

1643
DATE MAILED:

08/05/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. OTHER:

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123.
- For CRF submission help, call (703) 308-4212.
- For PatentIn software help, call (703) 308-6856.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE